Article
The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells.
PloS one - 1 Jan 2014
Wada Makoto, Horinaka Mano, Yamazaki Toshikazu, Katoh Norito, Sakai Toshiyuki
Abstract excerpt
Although melanoma is the most aggressive skin cancer, recent advances in BRAF and/or MEK inhibitors against BRAF-mutated melanoma have improved survival rates. Despite these advances, a treatment strategy targeting NRAS-mutated melanoma has not yet been elucidated. We discovered CH5126766/RO51267...
Topics
- Animals
- Cell Line, Tumor
- Coumarins
- Genes, ras
- Humans
- MAP Kinase Kinase Kinases
- Mice
- Mutation
- Neoplasms
- Protein Kinase Inhibitors
- Xenograft Model Antitumor Assays
- raf Kinases